Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to -$31.0 million.

  • Voyager Therapeutics' Cash from Operations fell 1101.26% to -$31.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$116.7 million, marking a year-over-year decrease of 37566.52%. This contributed to the annual value of -$15.3 million for FY2024, which is 11964.86% down from last year.
  • Latest data reveals that Voyager Therapeutics reported Cash from Operations of -$31.0 million as of Q3 2025, which was down 1101.26% from -$33.3 million recorded in Q2 2025.
  • Over the past 5 years, Voyager Therapeutics' Cash from Operations peaked at $123.6 million during Q1 2023, and registered a low of -$37.9 million during Q1 2025.
  • For the 5-year period, Voyager Therapeutics' Cash from Operations averaged around -$5.6 million, with its median value being -$20.7 million (2021).
  • As far as peak fluctuations go, Voyager Therapeutics' Cash from Operations skyrocketed by 26167.0% in 2022, and later plummeted by 368203.59% in 2024.
  • Quarter analysis of 5 years shows Voyager Therapeutics' Cash from Operations stood at $11.2 million in 2021, then plummeted by 209.37% to -$12.2 million in 2022, then tumbled by 94.05% to -$23.8 million in 2023, then skyrocketed by 38.85% to -$14.5 million in 2024, then tumbled by 113.7% to -$31.0 million in 2025.
  • Its Cash from Operations stands at -$31.0 million for Q3 2025, versus -$33.3 million for Q2 2025 and -$37.9 million for Q1 2025.